Latest news
Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs - MedCity NewsMedCity News · Mon, 10 Aug 2026 03:12:34 GMTCytokinetics Q2 Earnings Call Highlights - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 01:03:00 GMTBraveheart's shares soar after raising $384M in its debut - FirstWord PharmaFirstWord Pharma · Thu, 06 Aug 2026 20:57:08 GMTLexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 11:44:00 GMTTenaya’s TN-201 Gene Therapy Shows Hypertrophy Reduction in HCM Patients - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTNavigating Life with Hypertrophic Cardiomyopathy - Custer County ChiefCuster County Chief · Tue, 04 Aug 2026 00:27:49 GMTCytokinetics wins UK MHRA approval and NICE backing for MYQORZO (aficamten) in obstructive HCM - DealroomDealroom · Sat, 01 Aug 2026 07:14:54 GMTMHRA, NICE Fast-Track New Obstructive Cardiomyopathy Drug - MedscapeMedscape · Fri, 31 Jul 2026 11:58:27 GMT